Polymorphism at position ?308 of the tumor necrosis factor ? gene influences outcome of infliximab therapy in rheumatoid arthritis
| Autor: | Nathalie Balandraud, Bénédicte Mugnier, Denis Reviron, Albert Darque, Chantal Roudier, Jean Roudier |
|---|---|
| Rok vydání: | 2003 |
| Předmět: |
Adult
Male musculoskeletal diseases medicine.medical_specialty Genotype medicine.medical_treatment Immunology Arthritis Gastroenterology Arthritis Rheumatoid Rheumatology Predictive Value of Tests Internal medicine Immunopathology medicine Humans Immunology and Allergy Pharmacology (medical) Prospective Studies skin and connective tissue diseases Aged Autoimmune disease Chemotherapy Polymorphism Genetic Tumor Necrosis Factor-alpha business.industry Antibodies Monoclonal Middle Aged medicine.disease Infliximab Treatment Outcome Antirheumatic Agents Rheumatoid arthritis Female Tumor necrosis factor alpha business medicine.drug |
| Zdroj: | Arthritis & Rheumatism. 48:1849-1852 |
| ISSN: | 1529-0131 0004-3591 |
| DOI: | 10.1002/art.11168 |
| Popis: | Objective To test whether the G-to-A polymorphism at position −308 in the promoter of the tumor necrosis factor α (TNFα) gene influences response to infliximab therapy in patients with rheumatoid arthritis (RA). Methods We genotyped 59 RA patients by polymerase chain reaction and subdivided them into two groups: those with the A/A or A/G genotype and those with the G/G genotype. We compared the groups' clinical responses to infliximab treatment after 22 weeks, using the Disease Activity Score in 28 joints (DAS28). Results We found that 42% of patients in the A/A and A/G group and 81% of patients in the G/G group had improvement of at least 1.2 in the DAS28 score (P = 0.0086). The average improvement in the DAS28 score was 1.24 in the A/A and A/G patients and 2.29 in the G/G patients (P = 0.029). Conclusion These data suggest that patients with a TNFα −308G/G genotype are better infliximab responders than are patients with A/A or A/G genotypes. TNFα −308 genotyping may be a useful tool for predicting response to infliximab treatment. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text